ReviewClinical infectious diseases : an official publication of the Infectious Diseases Society of America2017
Progress in the Fight Against Multidrug-Resistant Bacteria 2005-2016: Modern Noninferiority Trial Designs Enable Antibiotic Development in Advance of Epidemic Bacterial Resistance.
Review in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 63 citations in OpenAlex.
- Novel Antibiotics May Be Noninferior but Are They Becoming Less Effective?: a Systematic Review.Antimicrobial agents and chemotherapy · 2020Pooled it
- Use of standard definitions for the extent of antibiotic resistance in bacteria: a systematic review and framework for future consensus definitions.JAC-antimicrobial resistance · 2026Review
- Prevalence and phenotypic characterization of carbapenem resistance in multidrug-resistant Gram-negative bacteria across selected healthcare facilities in the United Arab Emirates: a retrospective study.BMC infectious diseases · 2026Article
- Antibiotics re-booted-time to kick back against drug resistance.npj antimicrobials and resistance · 2025Review
- Reserve antibiotics: overcoming limitations of evidence generated from regulatory approval trials.Globalization and health · 2025Review
- Global Pull Incentives for Better Antibacterials: The UK Leads the Way.Applied health economics and health policy · 2023Article
- The versatile defender: exploring the multifaceted role of p62 in intracellular bacterial infection.Frontiers in cellular and infection microbiology · 2023Review
- The Value of the Information That Can Be Generated: Optimizing Study Design to Enable the Study of Treatments Addressing an Unmet Need for Rare Pathogens.Open forum infectious diseases · 2022Review
- Leaks in the Pipeline: a Failure Analysis of Gram-Negative Antibiotic Development from 2010 to 2020.Antimicrobial agents and chemotherapy · 2022Review
- A Metagenomic Nanopore Sequence Analysis Combined with Conventional Screening and Spectroscopic Methods for Deciphering the Antimicrobial Metabolites Produced byAntibiotics (Basel, Switzerland) · 2021Article
- Understanding Early and Late Endpoints in Registrational Trials of Community-acquired Bacterial Pneumonia.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021Article
- Secondary Structural Transformation of Bovine Lactoferricin Affects Its Antibacterial Activity.Probiotics and antimicrobial proteins · 2021Article
- Discordance Among Antibiotic Prescription Guidelines Reflects a Lack of Clear Best Practices.Open forum infectious diseases · 2021Article
- Antibiotics Approved for Marketing in Populations Specifically Excluded From Premarketing Trials, 1999-2018.Mayo Clinic proceedings · 2020Article
- Buying Time: The AMR Action Fund and the State of Antibiotic Development in the United States 2020.Open forum infectious diseases · 2020Article
- Characterization of Resistance in Gram-Negative Urinary Isolates Using Existing and Novel Indicators of Clinical Relevance: A 10-Year Data Analysis.Life (Basel, Switzerland) · 2020Article
- How Phages Overcome the Challenges of Drug Resistant Bacteria in Clinical Infections.Infection and drug resistance · 2020Review
- Elaboration of Consensus Clinical Endpoints to Evaluate Antimicrobial Treatment Efficacy in Future Hospital-acquired/Ventilator-associated Bacterial Pneumonia Clinical Trials.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2019Article
- A shot in the arm for new antibiotics.Nature biotechnology · 2019Article
- Estimating the size of the United States market for new antibiotics with activity against carbapenem-resistant Enterobacteriaceae.Antimicrobial agents and chemotherapy · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 1 country.
Funding
Abstract
From a public health perspective, new antibacterial agents should be evaluated and approved for use before widespread resistance to existing agents emerges. However, for multidrug-resistant pathogens, demonstration of superior efficacy of a new agent over a current standard-of-care agent is routinely feasible only when epidemic spread of these dangerous organisms has already occurred. One solution to enable proactive drug development is to evaluate new antibiotics with improved in vitro activity against MDR pathogens using recently updated guidelines for active control, noninferiority trials of selected severe infections caused by more susceptible pathogens. Such trials are feasible because they enroll patients with infections due to pathogens with a "usual drug resistance" phenotype that will be responsive to widely registered standard-of-care comparator antibiotics. Such anticipatory drug development has constructively reshaped the antibiotic pipeline and offers the best chance of making safe and efficacious antibiotics available to the public ahead of epidemic resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.